AUG 11, 2026 · PHASE 3 TRIAL
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
ClinicalTrials.gov
Phase 3 trial in active recruitment with no results posted; this registry record describes a planned study design and endpoints only, not outcomes.
Reported
Planned sample size927
Primary outcome measureRate of Pathologic Complete Response (pCR)
PhasePhase 3